摘要
目的:探讨艾塞那肽对不同体质量指数(BMI)2型糖尿病患者代谢指标的影响。方法:106例2型糖尿病患者按照不同BMI分为正常组(35例)、超重组(35例)和肥胖组(36例)。在原有降糖治疗基础上,给予3组患者艾塞那肽治疗。比较3组患者治疗前后的血压、体质量、BMI、各项血糖指标及甘油三酯水平,并观察其不良反应发生情况。结果:超重组与肥胖组患者治疗后的血压、体质量、BMI均显著优于治疗前,差异具有统计学意义(P<0.05)。3组患者治疗后的空腹血糖、餐后2 h血糖、糖化血红蛋白、甘油三酯水平均显著低于治疗前,差异具有统计学意义(P<0.05)。超重组与肥胖组患者的体质量和BMI变化幅度均显著大于正常组,差异具有统计学意义(P<0.05)。3组患者均未出现严重并发症。结论:艾塞那肽适合于超重、肥胖2型糖尿病患者的治疗。
OBJECTIVE：To explore the effects of Metabolic index of exenatide on body mass index（BMI）of type 2 diabetes patients.METHODS：According to different BMI,106 patients with type 2 diabetes were divided into normal group（35 cases）,overweight group（35 cases）and obesity group（36 cases）.Based on previous hypoglycemic therapy,3 groups received exenatide.Blood pressure,body weight,BMI,blood glucose index,TG and ADR were compared among 3 groups.RESULTS：After treatment,blood pressure,body weight and BMI of overweight group and obesity group were significantly better than before,with statistical significance（P〈0.05）;fasting blood glucose,postprandial 2 h blood glucose,glycosylated hemoglobin,triglycerides of 3group were significantly lower than before,with statistical significance（P〈0.05）.Changes of body weight and BMI in overweight group and obesity group were significantly higher than in normal group,with statistical significance（P〈0.05）.No serious complications was found in 3 groups.CONCLUSIONS：The therapy of exenatide is suitable for overweight and obese type 2 diabetic patients.
出处
《中国药房》
CAS
北大核心
2016年第2期240-241,共2页
China Pharmacy
